Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galbanic acid is a natural sesquiterpene coumarin and terpene lactone, primarily isolated from plants of the Ferula genus, such as Ferula assafoetida and Ferula sinkiangensis. It has demonstrated a range of pharmacological activities in preclinical studies, including anticancer (notably cytotoxic and pro-apoptotic effects in various cancer cell lines), anti-inflammatory, anticoagulant, antiviral, antileishmanial, and neuroprotective properties. Mechanistically, galbanic acid acts as an inhibitor of matrix metalloproteinases MMP2 and MMP9. In cancer models (e.g., non-small cell lung carcinoma), it induces apoptosis via caspase activation and inhibition of anti-apoptotic proteins like Mcl‑1. In neurological models (e.g., seizure/epilepsy), it reduces neuroinflammation by downregulating TNFα, IL1β, TLR4 expression and lowering nitrite levels in brain tissue[2][3][4][5]. The compound is under preclinical investigation for indications such as melanoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on galbanic acid.